Methilon Tablets (Methylprednisolone)

Adult use

The initial dose may vary from 4mg to 48mg of methylprednisolone per day, depending on the symptoms of the specific disease. In general, a low dose is sufficient for less severe conditions, but a high initial dose may be required in certain patients. The initial dose should be maintained or adjusted until a satisfactory response is obtained. If a satisfactory clinical result is not achieved after a reasonable period, discontinue treatment and switch to another appropriate therapy. The dose must be determined individually according to the various diseases being treated and the patient's response. After an adequate response is achieved, an appropriate maintenance dose should be determined by reducing the initial dose at suitable intervals until the lowest dose that maintains an adequate clinical response is reached. Continuous monitoring of the dose is required. Situations that may require dosage adjustment include remission or worsening of the disease, individual patient responsiveness to the medication, and the effect on the patient of exposure to stressful circumstances that are not directly related to the symptoms of the disease being treated. In the latter case, it may be necessary to increase the dose for a period sufficient to achieve satisfactory control of the patient's condition. After long-term treatment, gradual dose reduction is recommended when discontinuing the medication. For treatment of acute exacerbations of multiple sclerosis, administration of prednisolone 200mg daily for 1 week, followed by prednisolone 80mg every other day for 1 month, is effective (4mg of methylprednisolone is equivalent to 5mg of prednisolone). Alternate-day therapy is a regimen in which twice the daily dose is administered on one morning in every 2-day period. Although a single morning dose results in considerably less adrenal suppression than taking prednisolone (10mg) in 4 divided doses every 6 hours, there is evidence that when pharmacologic doses are used, a slight suppressive effect on adrenal activity continues into the following day. The initial suppressive dose should be continued until a satisfactory clinical response is obtained, usually for 4 to 10 days for many allergic and collagen diseases. Switch to ADT and gradually reduce the amount of corticosteroid given every other day. As disease progression is brought under control, reduce the daily corticosteroid dose to the minimum effective level as soon as possible, then switch to an alternate-day schedule. If this proves difficult, it is preferable to administer 3 times, or even 4 times, the daily dose every other day rather than merely twice the daily dose. Once the patient is again controlled, attempt to reduce this dose to the minimum. If an acute exacerbation occurs during disease progression, it may be necessary to return to a fully suppressive corticosteroid dose divided throughout the day to achieve control. Once control is achieved, the established alternate-day regimen can be tried again.

This medication should not be used in certain patients. For example, it should not be administered to patients who are allergic to this medication or its components, those with infections that are unresponsive to antibiotics, or systemic fungal infections, or patients with herpes simplex, herpes zoster, or chickenpox. Additionally, patients who are receiving live vaccines or attenuated live vaccines or those with lactose intolerance or genetic lactose enzyme deficiency should not use this medication. This medication should be used cautiously in some patients. Patients with glaucoma, tuberculosis, keratitis, cataracts, electrolyte disorders, hypertension, thrombosis, recent surgery, heart disease, peptic ulcers, mental illnesses, and osteoporosis should be especially careful while using this medication. This medication may suppress immune function, so caution should be exercised when administering it to patients with infections or those with diabetes, renal failure, hypothyroidism, fatty liver, myasthenia gravis, elderly individuals, epilepsy, ulcerative colitis, and so forth. Adverse effects may include fluid retention, edema, increased blood pressure, muscle weakness, osteoporosis, gastrointestinal issues, skin changes, neurologic abnormalities, endocrine disorders, and ocular issues. Long-term use may lead to adrenal insufficiency, so it should not be abruptly discontinued, and doses should be tapered gradually, with increased doses required in stressful situations. Due to the immunosuppressive effects, it can cause increased susceptibility to infections such as chickenpox or measles, so prevention and proper treatment of infections are necessary. This medication may interact with other drugs, so caution is advised when taken alongside drugs that can cause cardiac arrhythmias, anticonvulsants, anticoagulants, hypoglycemics, diuretics, antibiotics, etc. Pregnant or nursing women should consult their physicians before using this medication, as it may affect the fetus or newborn. In pediatric patients, growth retardation may occur, so the minimum effective dose should be used and growth should be closely monitored. Elderly patients may experience side effects more easily, such as infections, diabetes, osteoporosis, and hypertension, so careful administration is necessary. During the use of this medication, it is crucial to follow the physician's instructions and consult immediately if any unusual symptoms occur.

Edema, sodium retention, potassium loss, fluid retention, hypokalemic alkalosis, congestive heart failure, hypertension, myasthenia, aseptic necrosis of the femoral and humeral epiphyses, steroid myopathy, muscle atrophy, pathologic fracture of the pelvis, osteoporosis, vertebral compression fractures, arthralgia, tendon rupture, increased ALT, increased AST, increased ALP, nausea, dry mouth, vomiting, gastric pain, loss of appetite, increased appetite, peptic ulcer, abdominal distension, pancreatitis, ulcerative esophagitis, diarrhea, delayed wound healing, facial erythema, thin and fragile skin, abnormal sweating, petechiae, purpura, suppressed skin reactions, purpura, acne, hirsutism, alopecia, pigmentation, increased intracranial pressure, papilledema, seizures, dizziness, headache, insomnia, euphoria, depression, Cushing's syndrome, menstrual abnormalities, growth retardation in children, symptoms of latent diabetes mellitus, secondary adrenal insufficiency, pituitary non-responsiveness, decreased glucose tolerance, increased demand for insulin or oral hypoglycemic agents, suppression of adrenocorticotropic hormone secretion, increased intraocular pressure, glaucoma, posterior subcapsular cataract, secondary eye infection, central serous chorioretinopathy, retinal disorders, exophthalmos, negative nitrogen balance, immune system disorders, allergic reactions, shock, urticaria, anaphylactic reactions, hypersensitive reactions

This medication should be stored in a tightly closed container to prevent air or moisture from entering. The storage temperature should be maintained at room temperature between 1°C and 30°C. This helps to maintain the drug's effectiveness for a longer period and ensures safe use.

Appearance

White round tablet

Package unit

30 tablets/bottle, 300 tablets/bottle